Real-world characteristics and outcomes of advanced non-small-cell lung cancer patients with EGFR exon 19 deletions or exon 21 mutations - PubMed

Source : https://pubmed.ncbi.nlm.nih.gov/33866796/

Aim: To estimate real-world (rw) outcomes for first-line therapy in patients with advanced EGF receptor ( EGFR)-mutated non-small-cell lung cancer (NSCLC), focusing on specific mutation types. Patients & methods: Retrospective observational study (n = 244 patients). Results: Univariate/multivariate analyses showed longer rw progression-free survival (rwPFS) and rwPFS2 in patients with ex19del versus Leu858Arg mutations.